Nantahala Capital Management LLC Makes New Investment in BioCryst Pharmaceuticals, Inc. $BCRX

Nantahala Capital Management LLC purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,901,160 shares of the biotechnology company’s stock, valued at approximately $19,011,600.

Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of BioCryst Pharmaceuticals during the second quarter worth about $238,930,000. RA Capital Management L.P. bought a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $123,452,000. Jupiter Topco LLC bought a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $95,268,000. Deerfield Management Company L.P. boosted its position in BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after acquiring an additional 7,477,000 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in BioCryst Pharmaceuticals by 7,807.2% during the 4th quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock worth $57,791,000 after acquiring an additional 7,310,745 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

BCRX has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. HC Wainwright reissued a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Cantor Fitzgerald increased their price objective on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Finally, Needham & Company LLC decreased their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.60.

BioCryst Pharmaceuticals Stock Down 0.5%

Shares of BioCryst Pharmaceuticals stock opened at $9.82 on Friday. The stock has a market cap of $2.51 billion, a P/E ratio of -6.55 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.00 and a 12-month high of $11.22. The business’s 50 day moving average is $9.71 and its 200-day moving average is $9.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm’s revenue was up 33.6% on a year-over-year basis. During the same period last year, the business earned $0.15 earnings per share. On average, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.